Replies to post #43 on Senti Biosciences Inc (SNTI)

[jondoeuk]

I would be surprised if there were no responses to SENTI-202, but complete remission has long been the critical therapeutic response, ideally MRD-negative. Toxicity is another, as cytarabine (used for lymphodepletion with fludarabine) has potent immunosuppressive effects so that could lead to (additional) myelosuppression and infections. A third will be how well the logic-gated gene circuit (for the CARs) protects healthy hematopoietic stem cells.

As for SENTI-301A, I don't think there will be (RECIST) responses. For solid tumours, more will need to be done, such as additional engineering https://www.drugtargetreview.com/news/151575/treating-hcc-with-genetically-modified-nk-cell-therapy/

Finally, funding is a concern.